Accession Therapeutics is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumor diversity.
Accession Therapeutics was founded in 2020 by Bent Jakobsen, Francis Yuan, Nick Cross.
1282 health care and life sciences companies are in the directory, 519 of them in the same 11-50 employee range and 131 based in Europe.
Accession Therapeutics may be growing as it is preparing to advance its lead candidate into the clinic, which indicates progress in its product pipeline. Advancing a candidate into clinical trials is a significant step in the biopharma and biotechnology industry, as it demonstrates a move towards potential commercialization and revenue generation. This step typically follows successful preclinical development and can lead to increased investment and partnerships, further supporting the company's growth trajectory.
“Accession Therapeutics Limited is developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumour diversity.” accessiontherapeutics.com
Accession Therapeutics has a 11-50 person team and operates in biopharma, listed under Europe, and has been around since 2020. Its website drew about 728 visits in the latest month measured and its founders are Bent Jakobsen, Francis Yuan and Nick Cross.
11-50 employees · a-biodesign.com
11-50 employees · acernatec.com
11-50 employees · adm-labs.com
11-50 employees · 89bio.com
11-50 employees · 3tbiosciences.com
11-50 employees · alxoncology.com
501-1,000 employees · apcerls.com
501-1,000 employees · adaptimmune.com
1-10 employees · 101therapeutics.com
51-100 employees · 4sc.de
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.